Company: BDRX
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001214659-25-008576
Chunk: 2

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-30
Form: 424B3
Chunk 2
---
| Cash at bank                                  |     |        5.7 |
| Cash in escrow for eRapa Phase 3 program      |     |        4.4 |
|                                               |     |       10.1 |
| Undrawn CPRIT grant for eRapa Phase 3 program |     |       11.9 |
| Debt                                          |     |        0.5 |

The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially funded. Based
on its latest projections, the Company has sufficient working capital to fund operations into the first quarter of 2026.

Issued shares, total voting rights, market capitalization
As of May 29, 2025, there
were 50,506,308,922 ordinary shares, equivalent to 5,050,630 American Depositary Shares (ADSs), outstanding. The Company holds zero shares
in treasury and therefore the number of voting rights is the same as the number of ordinary shares outstanding.

Based on the closing share price on May 29, 2025 of $1.06 per ADS, the Company’s market capitalization
was $5.4 million.

eRapa Phase 3 program
The Phase 3 study of eRapa in FAP is in the final stages of
implementation. It will be a double-blind placebo-controlled trial in 168 patients, randomized 2:1 drug / placebo. It is expected the
study will be conducted in approximately 30 clinical sites across the US and Europe. The US component of the study will be conducted by
LumaBridge, based in San Antonio, Texas and the European component will be conducted by Precision for Medicine LLC. All planned US sites
and the majority of European sites have been identified. Recruitment is expected to begin in the next few weeks.

About FAP
FAP is characterized as a proliferation of polyps in the colon and/or rectum,
usually occurring in mid-teens. There is no approved therapeutic option for treating FAP patients, for whom active surveillance and surgical
resection of the colon and/or rectum remain the standard of care. If untreated, FAP typically leads to cancer of the colon and/or rectum.
There is a significant hereditary component to FAP with a reported prevalence of one in 5,000 to 10,000 in the US and one
in 11,300 to 37,600 in Europe. Importantly, mTOR has been shown